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Abstract
Background: Leprosy is curable with multidrug therapy and treatment in the early stages can prevent disability.
However, local nerve damage can lead to injury and consequently recurring and disfiguring ulcers. The aim of this
study is to evaluate the treatment of leprosy ulcers using an autologous blood product; leukocyte and platelet-rich
fibrin (L-PRF) to promote healing.
Methods: This is a single-centre study in the Anandaban Hospital, The Leprosy Mission Nepal, Kathmandu, Nepal.
Consenting patients (n=130) will be individually randomised in a single-blinded, controlled trial. Participants will be
18 years of age or older, admitted to the hospital with a clean, dry and infection-free chronic foot ulcer between 2
and 20 cm2 in size. If the ulcer is infected, it will be treated before enrolment into the study. The intervention
involves the application of leukocyte and platelet-rich fibrin (L-PRF) matrix on the ulcer beds during twice-weekly
dressing changes. Controls receive usual care in the form of saline dressings only during their twice-weekly dressing
changes. Primary outcomes are the rate of healing assessed using standardised photographs by observers blind to
allocated treatment, and time to complete re-epithelialization. Follow-up is at 6 months from randomisation.
Discussion: This research will provide valuable information on the clinical and cost-effectiveness of L-PRF in the
treatment of leprosy ulcers. An additional benefit is the evaluation of the effects of treatment on quality of life for
people living with leprosy ulcers. The results will improve our understanding of the scalability of this treatment
across low-income countries for ulcer healing in leprosy and potentially other conditions such as diabetic ulcers.
Trial registration: ClinicalTrials.gov ISRCTN14933421. Registered on 16 June 2020
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Introduction
Background and rationale {6a}
Leprosy is a chronic infectious disease that causes
neuritis with loss of sensation. Neuropathy is caused
primarily by inflammatory episodes called ‘reactions’,
which can occur in 30–50% of leprosy cases in response
to live Mycobacterium leprae or residual antigens
persisting for years in skin and nerve tissues after
curative treatment [1, 2]. Neuritis can develop and recur
at any time before, during or even years after leprosy
treatment [3]. The combination of loss of sensation and
deformities leads to the presentation of ulcers, often
with the first presentation within 4–5 years of leprosy
diagnosis, and then an increased lifetime risk of
recurrent ulcers, which can lead to deformity and
permanent disability.
Nepal, with over 3200 new cases of leprosy annually, is
one of 23 priority countries for the World Health
Organization’s (WHO) global national leprosy programme
[4]. The prevalence rate of leprosy is rising, though this
may be due to improved reporting and active case finding
[4]. While leprosy is curable with multidrug therapy,
Nepalese people may hide early symptoms due to stigma
based on cultural perceptions that leprosy is a punishment
for former life transgressions [5]. Thus, there are often
delays in presentation of leprosy, which can lead to the
development of complex ulcers requiring long hospital
stays. Furthermore, weight bearing and physical activity
are often adversely associated with healing rates of plantar
ulcers [6] but resting to prevent or heal an ulcer is
impractical for many affected people who need to work to
earn their living.
People afflicted with recurrent ulcers suffer severe
consequences in terms of loss of function, loss of
earnings, stigma, and often severe mental distress [7].
This protocol concerns the evaluation of a promising
intervention to promote the healing of leprosy ulcers,
and so improve wellbeing and quality of life for people
living with leprosy. Findings would also be relevant to
other ulcerative conditions, particularly diabetes, where
ulcers can similarly result from peripheral nerve damage.
Leprosy ulcers heal slowly, because they are large and/
or deep when they present and possibly because the skin
is less moist due to damage to autonomic nerves. Slow
healing leads to an extended stay in hospital, which has
implications for the patients, their family members and
for hospitals. Current methods of topical treatment
include applications of zinc tape, wax therapy, human
amniotic membrane gel, topical phenytoin, saline gel, or
emerging cellular therapies such as platelet-rich plasma
gel [8, 9]. However, results from intervention studies are
ambiguous [8] and recent Cochrane reviews have called
for higher quality research on ulcer treatment and pre-
vention in leprosy, specifically advocating for rando-
mised controlled trials (RCTs), ‘blinding’ of outcome
measurement and appropriate sample size [8, 10].
Autologous platelet-rich plasma (PRP) is a cellular
therapy with the potential to improve the healing of
chronic wounds and avoid limb loss [11]. A Cochrane
review suggested that it may be beneficial for diabetic
patients, although the effect size was modest and the tri-
als were not of high quality [12]. A trial of PRP to pro-
mote tendon healing did not find evidence that it was
effective [13]. A ‘second generation’ of the treatment,
leukocyte and platelet-rich fibrin (L-PRF), shows prom-
ise, albeit with inconclusive formal research evidence.
Results from one longitudinal study in Chile [14] showed
potential with a reduction in the size of wounds and
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closure of some chronic ulcers. However, patients acted
as their own controls and so the cause of the recovery
cannot be attributed to any particular aspect of the care.
A trial of L-PRF in neuropathic diabetic ulcers also dem-
onstrated positive results although the analysis was not
by intention to treat [11].
Irrespective of these inconclusive or null findings, this
therapy is currently used in low and middle income
(LMIC) countries [14], including Anandaban Hospital,
The Leprosy Mission Nepal. The use of the therapy here
suggests that the treatment would be scalable if proven
effective; however, reliable evidence from a randomised
trial is needed to support its continued or expanded use
given that it is more costly than conventional therapy.
Aim and objectives {7}
The aim of this study is to evaluate the efficacy of L-PRF
on healing rates for leprosy ulcers, time to healing and
duration of hospital stay.
The objectives are as follows:
 Recruit 130 eligible adults.
 Randomise participants to intervention (application
of leukocyte and platelet-rich fibrin (L-PRF) matrix
on the ulcer beds) or standard care (saline dressings
only).
 Monitor rate of healing based on two observations
per week (cm2 per unit time).
 Monitor the time to complete re-epithelialization
(up to a maximum of 70 days).
 Monitor participant activity using a pedometer.
 Measure health-related quality of life fortnightly
using the EQ-5D 3L.
 Compare the main and secondary end-points be-
tween treatment arms.
 Monitor recurrences of treated ulcers, appearances
of new ulcers and any anatomical changes in the
limb at follow up (6 months from randomisation).
 Undertake an economic evaluation to estimate the
impact of L-PRF on net population health in terms
of daily and quality adjusted life years (DALY/
QALYs).
Trial design {8}
A single-centre, prospective, single blinded, parallel
group, 1:1 individually randomised controlled trial. Study
duration is 48 months (maximum). Participants and
practitioners will not be blinded, but the assessors will
be completely blinded, as we describe in the section on
ulcer measurements. Each participant will be followed
up for up to 6 months from the point of randomisation.
Consent (see ethics) and baseline data collection will
precede randomisation. A summary of the study path-
way is shown in Fig. 1.
Methods: participants, interventions and
outcomes
Study setting {9}
The study will be conducted at the Anandaban Hospital
currently run under The Leprosy Mission Nepal. The
Anandaban Hospital lies in southern part of Lalitpur
district of Nepal, approximately 20 km south of
Kathmandu in the Bagmati province. Established in 1957
by The Leprosy Mission England & Wales, it is the
tertiary leprosy referral hospital in Nepal, with 110 beds
and provides specialist tertiary leprosy care for
approximately 6000 patient visits annually from all over
Nepal and the Northern part of India. It also provides
general medical care for the local population.
Eligibility criteria {10}
The inclusion criteria are as follows:
1. Patients with a chronic foot ulcer of at least 6
weeks duration due to leprosy neuropathy
2. ≥18 years of age.
3. Ulcer surface area between 2 and 20 cm2 inclusive.
4. Ulcer is clean, dry and free from infection.
5. Patient can provide informed consent.
The exclusion criteria are as follows:
1. Any significant medical condition, laboratory
abnormality, or psychiatric illness that would
prevent the participants from participating in the
study (e.g. diabetes or diabetic ulcer, HIV, chronic
Hep B, chronic Hep C or TB patients under active
treatment).
2. Ulcer with surface area <2cm2 and >20cm2.
3. Untreated high blood pressure > 150 mm HG
systolic
4. Haemoglobin less than 9 gm/dL or platelets <
100×103/ul
5. Patient requires skin graft.
6. Pregnant or breast-feeding.
7. Patients with Erythema Nodosum Leprosum (ENL)
or a leprosy reaction under steroid treatment.
8. Any wound that has clinical microbial infections.
9. A patient who has returned to the hospital having
previously been a participant in the trial.
Who will take informed consent {26a}
A local research fellow trained in Good Clinical Practice
(GCP) will screen all admissions for eligibility. Eligible
patients will be provided with a Patient Information
Leaflet and verbal information as necessary about the
study from a research fellow in local languages. Written
informed consent will be sought the following day, once
eligibility has been confirmed. Thumb or fingerprints
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will be requested in lieu of a signature if necessary.
Translated consent forms have been back-translated ac-
cording to the WHO methodology [15] for quality assur-
ance purposes.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Consent includes the option to give permission for the data
collected to be used in future research. Participants can
reject this option and still take part in the TABLE trial.
Intervention
Intervention description {11a}
The intervention uses the participant’s own blood to
prepare strips of leukocyte and platelet-rich fibrin matrix
(L-PRF) to be applied to the ulcer bed. The process is
described in detail elsewhere [16] but briefly, up to 80ml
of participants’ blood will be collected twice per week at
the time of dressing change. The blood will be centri-
fuged to obtain the fibrin matrix gel, which will be com-
pressed and applied to the ulcer bed and then covered
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Fig. 1 Summary of study pathway and participant timeline
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participants, centrifugation procedure and application of
L-PRF will be done in a minor operating room following
aseptic technique. All participants (including those in
the control group) will be given iron and folic acid tab-
lets. Both control and intervention groups will receive
routine twice-weekly dressing changes by trained nurses
or paramedics until their ulcers are healed (complete re-
epithelization) up to a maximum of 70 days. Any missed
dressing change sessions will be noted but not treated as
a deviation from the protocol.
In the event that a participant has more than one
ulcer, the largest ulcer will be selected as the index ulcer
for analysis purposes before randomisation. However, all
of the participant’s ulcers will receive the same
treatment. Thus, if the participant is in the intervention
group they will receive L-PRF treatment on all of their
ulcers. Eligible patients will be offered entry in the trial
at the point where their clinician judges them suitable
for treatment, i.e., when the lesion is clear of any debris
or infection.
Activity measurement
All participants will be invited to wear a pedometer
(Model: Mi Smart Band 5, Model: XMSH10HM) on the
ankle of their non-affected limb (or non-index case af-
fected limb) which they will wear from the first dressing
change until 42 days (the point where cross-over may
occur) or discharge, whichever comes first. This will act
as a proxy measure of weight bearing and enable us to
monitor activity across intervention and control groups
and thereby evaluate whether the level of activity is simi-
lar across groups.
Explanation for the choice of comparators {6b}
The comparator is usual care. Participants in the control
group will receive usual care of twice-weekly standard
saline dressings only and will not have blood taken. The
clinical care of these participants will be identical to the
intervention participants.
Criteria for discontinuing or modifying allocated
interventions {11b}
Details of any concomitant illness or medication
(present at start of the trial) will be recorded at trial
entry. If any change influences the participant’s eligibility
to continue in the trial, the local Principal Investigator
will be informed and a decision to continue with the
intervention will be made in the participant’s best
interest. The intervention may also be discontinued at
participant’s request. Participants who withdraw will
receive usual care.
Strategies to improve adherence to intervention {11c}
None.
Relevant concomitant care permitted or prohibited during
the trial {11d}
Given that weight bearing and physical activity are
adversely associated with healing rates of plantar ulcers,
all participants will be encouraged to rest during the trial.
Provisions for post-trial care {30}
Discharge information will be noted along with the
participant and a family member’s contact details. Each
trial participant will receive a cell phone and contact
details to use in the event of any difficulties. Any
readmissions at Anandaban Hospital, or any other
hospitals for treatment of the same ulcer (the ‘trial
ulcer’), will be recorded (both dates and duration).
Outcomes {12}
The main end-points will be:
1) ‘Rate of healing’ based on two observations per
week of ulcer size censored at 42 days (cm2 per unit
time). We will estimate the effect of the
intervention on the change in the ulcer size per
unit time, i.e. the rate of healing (see Statistical
Analysis).
2) Time to complete re-epithelialization (right-cen-
sored at 42 days).
Both end-points will be analysed with and without ad-
justment for baseline characteristics (trial ulcer area and
participants’ age), but we prefer unadjusted outcomes in
randomised studies and therefore declare them as
‘primary’.
Secondary end-points:
1) Rate of healing based on two observations per week
up to 70 days (cm2 per unit time) (calculated as
described below).
2) Time to complete re-epithelisation (observed up to
70 days).
3) Generic quality of life (QoL) measured at first
dressing change, fortnightly during in-patient stay
and at 6-month follow-up, using the EQ-5D 3L.
This scale has previously been used and validated in
a Nepali population [17]. As far as we are aware,
there is no valuation tariff in the Nepalese popula-
tion, although this may change by the time that the
analysis starts. Therefore, we propose not to pre-
specify the tariff but instead select the tariff at a
later date. We note that tariffs are currently avail-
able for nearby countries including Sri Lanka [18]
and China [19, 20].
4) Longer-term outcomes measured at 6-month
follow-up from randomisation will be proportion
with:
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i. Recurrence of treated ulcer;
ii. Appearance of new ulcer;
iii. Anatomical changes in the limb;
5) Days hospitalised prior to discharge and total (to
include any readmission due to leprosy/ulcers) by 6
months.
6) Health economic information:
i. Number of visits to any healthcare facility from
discharge to the end of follow-up at 6 months.
ii. Data on the time taken to change dressings at
the twice weekly changes.
Rate of healing will be assessed from blindly assessed
photographs (Fig. 2). However, as complete healing may
trigger discharge, we will monitor for cases discharged
before the blinded assessor in Birmingham has noted
complete re-epithelization.
Level of activity (step count) will be collected daily
and monitored across both intervention and control
groups until 42 days (the point where cross-over may
occur) or discharge, whichever comes first—see ana-
lysis below.
Participant timeline {13}
See Fig. 1 for the participant’s timeline through the trial.
Patients provide consent for randomisation when they
have been confirmed to be eligible (including lesion free
of debris and infection). See also ‘who will take informed
consent’ above.
Sample size {14}
Sample size is based on the two primary outcomes: rate
of healing and time to complete re-epithelialization. On
the latter, we assume that 70% of ulcers will heal within
42 days with standard care [21]. Further, assuming that
the intervention will increase this proportion to 90% and
hazards are constant and proportional, for a two-sided
test of the hazard ratio with a type I error of 5% and
statistical power of 80% and a 1:1 allocation ratio, 47 in-
dividuals are required in each group. To allow for with-
drawals and right censoring, we aim to recruit 65
patients in each group. We expect rate of healing to pro-
vide yet more precise estimates.
Recruitment {15}
Eligible individuals are identified by the clinical research
team and invited to participate by the local research
fellow (see eligibility criteria).
Assignment of intervention: allocation
Sequence generation, concealment mechanism and
implementation {16a, 16b, 16c}
Participants will be enrolled sequentially and randomly
allocated (1:1) to undergo L-PRF treatment or usual care
using a ‘digital sealed envelope’ method [22]. An alloca-
tion table will be generated remotely by the trial statisti-
cian at The University of Birmingham to allocate
participants in a 1:1 ratio at the level of the individual
over the course of the trial. A random number generator
will be used to generate a random sequence of the
Fig. 2 ‘Closed loop’ ulcer assessment process
Napit et al. Trials          (2021) 22:453 Page 6 of 13
numbers between 1 to N inclusive. A permuted block
randomisation method will be used by randomly select-
ing blocks of size 2, 4, 6 or 8 in order to maintain bal-
ance between the numbers allocated to each of the two
groups. The generated table will be uploaded into the
REDCap software to be used for participant enrolment.
Access to the allocation table will be restricted. When a
participant’s details are submitted, the trial arm and a
unique study number will be assigned and revealed to
the local clinician so that the randomised group that the
participant is assigned to cannot be altered.
Assignment of interventions: blinding
Who will be blinded {17a}
The Nepal research team, the database managers in
Birmingham, the clinical staff carrying out dressing
changes in the room designated for this purpose and
participants themselves will be aware of participants’
randomly assigned group. Ward staff will not be
informed. Researchers in Birmingham involved in the
data analyses will be blinded to treatment allocation
(Fig. 2).
Procedure for unblinding {17b}
There is no requirement for an emergency unblinding
procedure.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Demographic data (age and sex), clinical data (number
and size of ulcers), concurrent diseases will be collected
for all consenting participants before randomisation
(Fig. 1). Data on quality of life (QoL) will be collected
fortnightly from first dressing change until discharge.
Ulcers will be assessed twice weekly (see below) during
the participant’s hospital stay, to a maximum of 70 days,
and then again at a 6-month follow-up visit. Steps taken
will be collected daily until 42 days (the point where
cross-over may occur) or discharge, whichever comes
first. Follow-up data collection at 6 months will require
an outpatient appointment or a home visit (Fig. 3). Data,
including photographs of ulcers, will be collected on
electronic tablets using the Research Electronic Data
Capture (REDCap) system by local researchers.
Ulcer measurements
Standardised photographs [23] will be taken twice
weekly during inpatient stay dressing changes for
participants in both intervention and control groups.
Photographs will be obtained in Nepal using two
different methods (Fig. 4). The photographs will be
transferred to the University of Birmingham and the
ulcer dimensions measured in three ways. Two
observers will be trained to take these measurements.
Both observers will be blinded to the participant’s
allocated treatment. All photographs from a given
participant will be assigned to the observers at
random, separately for the two methods of
photography. So that the measurements are not all
relegated to the end of the study, they will be made
in batches of ten participants reaching completion of
their baseline treatments (at complete re-
epithelization or 70 days from randomisation). A pro-
portion (20%) of all ulcer photographs will be mea-
sured by both observers to test inter-rater reliability.
These photographs will be selected at random.
The date at which complete re-epithelization took
place will be determined by the local clinician. Photo-
graphs will be taken at the point of complete re-
epithelialization and during the follow-up visit.
ARANZ® SilhouetteStar photography
For the first two measurement methods, a photograph
will be taken using the ARANZ® SilhouetteStar device
(camera) and the image synchronised to the participant’s
trial number and saved to the secure ARANZ®
SilhouetteCentral SQL server. This will be assessed by a
designated observer at the University of Birmingham.
The validated ARANZ 3D wound measurement software
tool will then be used to measure the ulcer in two ways.
The first measurement will be made using a manual
tracing method whereby the ulcer boundary will be
‘hand’ drawn in the ARANZ® software. The software will
then calculate the ulcer dimensions based on this
outline. The second measurement will utilise an
automatic tracing feature in the software. In this
instance, the observer will delineate a region of interest
(extending beyond the boundary of the ulcer) and the
software will automatically locate the boundary and
calculate the wound dimensions.
Digital tablet
The final measurement will use a photograph taken
using the in-built camera in the tablet devices (Sam-
sung Galaxy Tab S6). The photograph will be taken
perpendicular to the ulcer. For calibration purposes, a
3-cm size clean paper ruler with date and partici-
pant’s trial identification number will be placed in the
photograph frame above or below the ulcer but at the
level of the skin. The photograph will uploaded to
the server at the University of Birmingham and evalu-
ated digitally by a designated observer in Birmingham
using the PictZar™ Digital Planimetry Software [24]
with an electronic PUSH Tool (National Pressure In-
jury Advisory Panel (NPIAP) at https://npiap.com/
page/PUSHTool). The observer will delineate an area
of interest by manually ‘painting’ the ulcer area with
colour using a computer mouse. The software will
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then calculate the ulcer dimensions based on this
profile.
All observations will be made blind to treatment
allocation. The ‘closed loop’ ulcer assessment process is
shown in Fig. 2. The changes in surface area can then be
determined between each observation using three
methods of assessment (Fig. 4).
Plans to promote participant retention and complete
follow-up {18b}
Each trial participant will receive a cell phone to enable
the research team to contact them regarding their 6-
month follow up.
Data management {19}
Each participant will be allocated a unique participant
identification number which will be used on all electronic
documents and photographs. Data will be collected by
researchers in Nepal and entered on to the REDCap platform
hosted on a secure server at the University of Birmingham.
Ulcer photographs taken using the ARANZ® device will be
saved to the secure SilhouetteCentral SQL server. Data will
be encrypted and access will be password restricted.
Confidentiality {27}
All collected data will remain confidential. All data will
be stored in accordance with GCP and General Data
Fig. 3 Schedule of enrolment, intervention and assessment
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Protection Regulations 2018 (GDPR), and the Data
Protection Act 2018.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis {33}
None
Analyses and inference
Statistical methods for main endpoints {20a}
Time to healing Time to healing will be analysed using
a Cox proportional hazards model with and without
adjustment for baseline characteristics (trial ulcer area
and participants’ age) allowing for right-censoring. For
the rate of healing analysis, we will define the outcome
as the ulcer size in cm2 at each time point and include
in the model time since admission, treatment status and
their interaction. Our parameter of interest will be that
of the interaction term, which will be interpreted as the
mean difference in rate of healing (in cm2 per unit time)
between intervention and control groups. We will ana-
lyse this model using a linear mixed-effects model with
participant-level random effects and both with and with-
out adjustment for participant characteristics. Given
there are multiple primary outcomes (two outcomes,
with and without adjustment, for three types of ulcer as-
sessment), we will adjust reported p values for multiple
testing using a stepdown method, which provides an effi-
cient means of controlling the family-wise error rate
[25]. We will derive the approximate distributions of the
test statistics to perform the stepdown procedure using
a permutation test approach, by simulating 10,000 re-
randomisations of the individuals [26].
Measurements The above analyses of healing rate and
time of complete re-epithelialisation will be made separ-
ately for each method of measurement. Photographs will
be assessed blind to allocated treatment by two trained
observers at the University of Birmingham (Fig. 2).
Inter-rater reliability of the measurements will be made
on 20% of ulcer photographs and assessed using inter-
class correlation coefficients.
Measurements are based on the ARANZ ® and tablet-
based cameras (see Fig. 2). The ARANZ® images are
measured in two ways: (1) manual tracings and (2)
automatic tracings of wounds using a camera specifically
designed to obtain standardised photographs of ulcers
for scientific purposes. The distance of the camera from
the ulcer surface is controlled by triangulation of three
laser lights. The images taken by the camera in the
tablet are calibrated digitally by reference to a
measurement ruler in the frame. The areas (cm2) are
then generated within the different software packages.
We will measure, agreement between the methods of
measurement:
1. The Push tool vs. the automated ARANZ® method
2. The automated vs. manual ARANZ® method
Interim analyses {21b}
An interim analysis will be conducted when at least 49
participants have been followed-up for a minimum of 42
days. The rationale for this analysis is the detection of a
‘penicillin-like’ benefit or statistically significant negative
effect of the treatment on either of the two main end-
points. A statistical threshold of 0.01, one-sided (0.02
two-sided) will be used for either of the two main end-
points. In the event that more than 10% of control par-
ticipants cross-over from one arm to another at 42 days,
we will consider performing a complier average causal
effects analysis to the 70 day outcome.
Missing data {20c}
We will analyse by intention to treat. In the (extremely
unlikely) event that some participants withdraw before
complete healing and that rate differs between groups, a
sensitivity analysis will be applied. We will explore the
patterns and extent of any missing data, particularly
those relating to the two main endpoints. We do not
plan to impute missing values, but may consider the use
of multiple imputation or other strategies within the
sensitivity analysis if necessary.
Methods for additional analyses {20b}
Quality of life Quality of life (QoL) will be analysed by
calculating and comparing area under the curve (AUC)
across intervention and controls. Baseline results will be
triangulated with clinical observations to avoid bias and to
determine how differences in healing rates correspond to
differences in quality of life end-points.
Fig. 4 Ulcer capture and measurement process
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Activity measurement We will also compare average
daily step count between treatment and control groups
as a simple difference in means (t test). Since one group
may stay longer in hospital than the other and since
there may be an interaction between rate of healing and
step count, we will compare step counts over periods
pre-set at 7, 14 and 42 days.
Economic evaluation An economic evaluation of L-PRF
will be undertaken. The model will estimate the impact
of L-PRF on net population health in terms of daily and
quality adjusted life years (QALYs/DALY) over a long-
term time horizon. The effectiveness of the treatment
will be reflected by estimating the statistical relationship
between the primary end-point in the efficacy trial and
HRQoL (health-related quality of life) based on partici-
pants’ completion of the generic quality of life instru-
ments. This analysis will also reflect other characteristics
of participants that are potentially prognostic and pre-
dictive of the efficacy of L-PRF. The analysis will provide
a careful assessment of how the cost-effectiveness of L-
PRF varies according to its local acquisition cost, as well
as other parameters that could vary between localities.
Full uncertainty analysis will be undertaken to establish
whether there is sufficient evidence to support local
funding of L-PRF at a given acquisition cost or whether
additional evidence generation is necessary and worth-
while. We shall develop the model before the data to
populate it are available and our work-plan will included
a review of the relevant literature in countries with both
high and low incomes.
Reporting Where a participant withdraws from the
intervention as a whole, no further data will be collected.
Where the participant withdraws from the randomised
intervention but agrees to contribute data, they will be
followed-up to the point of discharge as an inpatient.
The trial will be reported in line with the CONSORT
(Consolidated Standards of Reporting Trials) Standards
[27, 28].
Plans to give access to the full protocol, participant level
data and statistical code {31c}
The full protocol, non-identifiable participant level data
and statistical code may be available for sharing once the
trial has ended. All requests will be approved by the
Chief Investigator (CI), Professor Richard Lilford (r.j.
lilford@bham.ac.uk).
Oversight and monitoring
Composition of the co-ordinating centre and trial steering
committee {5d}
The trial will be overseen by the Trial Management
Group (TMG) and a Trial Steering Committee (TSC).
The TMG will be responsible for the day-to-day man-
agement of the trial. It includes individuals at the Uni-
versity of Birmingham (Chief Investigator, Trial
Manager, Trial Co-ordinator, Clinical Trials Unit man-
agement staff) and Anandaban Hospital, The Leprosy
Mission Nepal (Principal Investigator, local Project Man-
ager and patient representatives). The TMG will meet
monthly by teleconference. The Trial Steering Commit-
tee provides overall supervision of the trial and will en-
sure that it is conducted in accordance with the
principles of Good Clinical Practice and other relevant
regulations. Meetings will be scheduled before enrol-
ment and after each meeting of the Independent Data
Monitoring Committee and more frequently during the
analysis phase. The TSC includes an independent chair
and members with clinical expertise.
Composition of the Data Monitoring Committee, its role
and reporting structure {21a}
The Data Monitoring Committee will review safety and
efficacy data during the active phase of the trial. They
will advise on the continued recruitment of trial
participants. They will meet either by teleconference or
face-to-face. This committee consists of an independent
chair, a statistician and members with clinical and meth-
odological expertise.
Adverse event reporting and harms {22}
The Principal Investigator in Nepal, Dr. Indra Napit, is
responsible for recording all adverse events (AEs) and
reporting any serious adverse events (SAEs) to the Chief
Investigator and University of Birmingham Clinical
Trials Unit (BCTU) within 24 h of becoming aware of
such an event. A SAE form will be available on the data
collection tablets and a database of any events will be
maintained. The Trial Management Group, Chief
Investigator and the BCTU will review any SAE forms.
The Trial Steering Committee will periodically review all
safety data and liaise with the Independent Data
Monitoring Committee regarding any safety issues. Any
deaths will be reported to the Sponsor irrespective of
whether the death is related to the disease progression,
the intervention or an unrelated event.
Frequency and plans for auditing trial conduct {23}
The trial is audited and monitored by the Sponsor, the
University of Birmingham.
Plans for communicating important protocol amendments
to relevant parties (e.g. trial participants, ethical
committees) {25}
Any protocol amendment will be reported to the Trial
Management Committee for approval. The Sponsor,
University of Birmingham Biomedical and Scientific
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Research Ethics Committee and the Nepal Health and
Research Council will subsequently be notified.
Dissemination plans {31a}
We will publish and disseminate through the usual
academic channels, including peer reviewed journals and
at academic conferences. Our dissemination plans
include close liaison with The Leprosy Mission to
engage affected people and communities and to ensure
that the results are disseminated widely. Other
dissemination plans include bite-sized research reports
in lay format, public announcements in communities in
LMICs, policy briefings, print and online media, the
Chief Investigator’s News Blog (680+ subscribers), insti-
tutional and professional social media accounts and
websites.
Discussion
This protocol describes an individually randomised
control trial to evaluate a treatment using autologous
blood products L-PRF, to promote ulcer healing in lep-
rosy. Despite the promising anecdotal evidence regard-
ing this treatment, high-quality, empirical data are
currently unavailable [12, 14].
Most of the evidence on ulcer healing, including the
Cochrane review [12], is based on proportion of ulcers
healed (completely epithelialized) by 42 days. This is
sub-optimal because complete epithelialisation is a clin-
ical decision that is also used to decide on discharge.
This provides an opportunity for observer (outcome)
bias. For this reason, we will measure rate of healing.
These measures are all made centrally (in Birmingham)
by two observers who are ‘blind’ to intervention status.
Activity measurements are not a primary outcome
measure in our study. However, by collecting step-count
daily and over the course of the inpatient stay over the
periods specified above, we can exclude activity as a con-
founding factor in any differences found in ulcer healing
rates between intervention and control groups.
We are also planning to do a range of nested studies.
Given sufficient time and resources, we hope to video
tape a subset of dressing changes (five intervention and
two controls selected at random in Birmingham) as a
means of photograph supervision and for additional
quality control. We will also develop a more detailed
health economics protocol. Finally, we will develop
follow on studies based on the results of the trial.
We are using three methods to measure the rate of
ulcer healing and time to complete re-epithelialisation.
Readers might wonder at such an extensive set of
methods and consider this ‘overkill’. Our rationale for
using these multiple ulcer measurement methods is two-
fold. First, it is crucially important in our judgement to
create a situation where results cannot be explained
away by measurement error (for all that measurement
error is more of a threat to precision than to accuracy).
Second, we wish to contribute to the methodological lit-
erature on ulcer measurement. As investigators we hope
that the results will be consistently null or positive (or
even negative). However, we realise that we may end up
with results that toggle around the conventional statis-
tical threshold , say, according to ulcer measurement
method or whether or not adjustment had been carried
out for any discrepancy in ulcer size at base-line. In that
case, we will simply report the different results and allow
the reader to make an interpretation. We will not (miss)
use statistical tests as decision rules.
By using a randomised control method, alongside
standardised blindly assessed photographs, and information
on activity, this research will provide robust evidence on the
clinical and cost-effectiveness of L-PRF in the treatment of
leprosy ulcers. Data collection and ulcer assessment follows a
‘closed-loop’ such that the photograph and image can follow
only one pathway from camera to completed measurement.
An additional benefit is the evaluation of the effects of treat-
ment on quality of life for people living with the effects of
leprosy. The findings will also be relevant to other ulcerative
conditions, particularly diabetes, where ulcers similarly result
from peripheral nerve damage. The results will improve our
understanding of the scalability of this treatment across low-
income countries for ulcer healing in leprosy and other simi-
lar conditions.
Trial status
Protocol version number: Version 2.0; 25.11.20
The TABLE trial is currently recruiting. The first
patient was randomised on 18th September 2020. The
Trial Management Group (TMG) and a Trial Steering
Committee (TSC) met before the first patient was
enrolled. We anticipate that it will take approximately
12–18 months to complete the recruitment phase.
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